Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
2000 · Cell · 1,773 citations
https://doi.org/10.1016/s0092-8674(00)00062-3
G
Gilles Lambert
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
264
Papers
14.3K
Citations
55
h-index
110
i10-index
Gilles Lambert is an academic researcher from Institut National de Santé Publique du Québec. The author has contributed to research in topics: Lipoproteins and Cardiovascular Health & Diabetes, Cardiovascular Risks, and Lipoproteins & Cancer, Lipids, and Metabolism. The author has an h-index of 55, co-authored 225 publications.
ORCID: 0000-0001-5632-0685Papers by this author
worksLipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
2022 · European Heart Journal · 1,124 citations
https://doi.org/10.1093/eurheartj/ehac361
Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice
2005 · Journal of Lipid Research · 173 citations
https://doi.org/10.1194/jlr.m500390-jlr200
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
2023 · Atherosclerosis · 134 citations
https://doi.org/10.1016/j.atherosclerosis.2023.04.012
Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells
2005 · Journal of Lipid Research · 100 citations
https://doi.org/10.1194/jlr.m400396-jlr200
Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
2012 · Journal of Lipid Research · 64 citations
https://doi.org/10.1194/jlr.p023994
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat